PBH

AI Memo

Prestige Consumer Healthcare

As of 2026-09-18/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-18 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Delivery against increased FY2027 outlook • 2027-03-31

Base target: $52 / p=45% prob

Biggest risk

The deterministic directional prior has turned negative despite constructive Q1 results. Clear Eyes underperformed management expectations, some quarterly strength reflected retailer order timing, and acquisition integration, inflation, supply-chain conditions, and an operations leadership transition could weaken delivery.

Invalidation

Break below $38 or thesis failure.

What would change my mind?

Broad-based Q1 growth, record adjusted free cash flow, increased full-year outlook, and two completed acquisitions support a path to faster portfolio growth and continued capital deployment if integration proceeds smoothly.

Research note

Recommendation

—

Confidence

medium

As of

2026-09-18

Base target

$52

p=45%

Bull target

$62

p=25%

Bear target

$38

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Operations leadership transition
Breathe Right and LaCorium integration
Broad-based Q1 growth, record adjusted free cash flow, increased full-year outlook, and two completed acquisitions support a path to faster portfolio growth and continued capital deployment if integration proceeds smoothly.

BearKey bullets

Clear Eyes sales were below management expectations in Q1.
Integrating Breathe Right and LaCorium may introduce execution, margin, and capital-allocation risk.
Management identified continuing uncertainty from supply-chain constraints, inflation, and geopolitical events.

WatchKey bullets

Delivery against increased FY2027 outlook

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $52 (p=45%)

Target spread vs base: +19% / -27%

Scenario probabilities

Bull Target: $62 (p=25%)Base Target: $52 (p=45%)Bear Target: $38 (p=30%)

Commentary

Available news coverage is limited but generally constructive around the Q1 beat, increased outlook, acquisitions, and record adjusted free cash flow. However, social coverage is absent, and options skew, short interest, employee sentiment, post-print price-reaction attribution, and analyst revisions are unavailable. Combined with the negative deterministic return prior, this supports a cautious monitoring stance rather than a high-conviction rerating call.

As of 2026-09-18 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Operations leadership transition
Breathe Right and LaCorium integration

Scenarios

Bull Target (Scenario probability)

$62 / p=25% prob

Base Target (Scenario probability)

$52 / p=45% prob

Bear Target (Scenario probability)

$38 / p=30% prob

Analysis 2026-09-18 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.15

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2027-03-31
Delivery against increased FY2027 outlook
Management said Q1 sales rose 6.5% to approximately $266 million, adjusted EPS reached $0.98, and adjusted free cash flow set a quarterly record at $83.7 million after results exceeded expectations; sustaining that performance against the increased full-year outlook is the principal rerating test. [#PR-EARNINGS-2026-08-13] [#SEC-8K-2026-08-06]
Prob 65.00% • Move 8.00% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

Operations leadership transition
2026-12-31
The Senior Vice President of Operations retired effective August 14, 2026. No disruption was identified in the filing, but the transition adds execution risk while PBH integrates acquisitions and manages supply-chain uncertainty. [#8-K-2026-08-14]
Prob 100% • Move -3% • Priced-in 85%

Long-term Catalysts

Months to a year

Breathe Right and LaCorium integration
2027-03-31
The two recently completed acquisitions broaden the consumer-health portfolio, with Breathe Right contributing approximately $6 million of Q1 revenue. Successful integration, brand investment, cash conversion, and disciplined capital allocation could improve medium-term growth, while execution problems would pressure returns. [#PR-EARNINGS-2026-08-13]
Prob 65% • Move 10% • Priced-in 45%

Risks

Clear Eyes sales were below management expectations in Q1.
Integrating Breathe Right and LaCorium may introduce execution, margin, and capital-allocation risk.
Management identified continuing uncertainty from supply-chain constraints, inflation, and geopolitical events.
Post-earnings analyst revisions and a sourced market-reaction explanation are unavailable.
Retailer order timing contributed to reported quarterly performance and may not represent durable underlying demand.
The operations leadership transition warrants monitoring during acquisition integration.

Peers

Symbol	Summary
AMLX	Similar market capitalization and broad sector classification, but development-stage pharmaceutical exposure makes AMLX a loose valuation peer rather than a direct operating comparable for PBH's consumer-health brands.
CDNA	Similar market capitalization and sector classification, but diagnostics exposure and a different revenue model materially limit operating comparability with PBH.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-18

Loading AI feed…

Symbol

Summary

AMLX

Similar market capitalization and broad sector classification, but development-stage pharmaceutical exposure makes AMLX a loose valuation peer rather than a direct operating comparable for PBH's consumer-health brands.

CDNA

Similar market capitalization and sector classification, but diagnostics exposure and a different revenue model materially limit operating comparability with PBH.